RESEARCH COMMUNICATION

Hypoxia-Inducible Factor 1 Promoter-Induced JAB1 Overexpression Enhances Chemotherapeutic Sensitivity of Lung Cancer Cell Line A549 in an Anoxic Environment

Ming-Dong Hu1*, Jian-Cheng Xu1*, Ye Fan1, Qi-Chao Xie2, Qi Li1, Chang-Xi Zhou3, Mei Mao4, Yu Yang1

Abstract

The presence of lung cancer cells in anoxic zones is a key cause of chemotherapeutic resistance. Thus, it is necessary to enhance the sensitivity of such lung cancer cells. However, loss of efficient gene therapeutic targeting and inefficient objective gene expression in the anoxic zone in lung cancer are dilemmas. In the present study, a eukaryotic expression plasmid pUC57-HRE-JAB1 driven by a hypoxia response elements promoter was constructed and introduced into lung cancer cell line A549. The cells were then exposed to a chemotherapeutic drug cis-diamminedichloroplatinum (C-DDP). qRT-PCR and western blotting were used to determine the mRNA and protein level and flow cytometry to examine the cell cycle and apoptosis of A549 transfected pUC57-HRE-JAB1. The results showed that JAB1 gene in the A549 was overexpressed after the transfection, cell proliferation being arrested in G1 phase and the apoptosis ratio significantly increased. Importantly, introduction of pUC57-HRE-JAB1 significantly increased the chemotherapeutic sensitivity of A549 in an anoxic environment. In conclusion, JAB1 overexpression might provide a novel strategy to overcome chemotherapeutic resistance in lung cancer.

Keywords: Lung cancer - hypoxia-inducible factor - JAB1 - chemotherapeutic sensitivity - resistance - cisplatin

Introduction

Lung cancer is a leading cause for cancer-related deaths worldwide, developing in more than a million new patients annually (Toh, 2009). Although great efforts have been employed to treat lung cancer in the clinic, 5-year survival rate is only 14% approximately. Low sensitivity of lung cancer cells to chemotherapy is one of the important factors responsible for the poor prognosis of lung cancer. Chemotherapy is a most widely used strategy in the management of lung cancer. In generally, cytotoxic drugs will cause apoptosis in major tumor cells, leaving a small number of survived tumor cells. For limited apoptosis and sublethal damage, it can not initiate normal apoptosis process (Pommier et al., 2004). Thus, it is urgent to clarify the related mechanism and overcome the chemoresistance.

Hypoxia, a common feature of solid tumors, occurs in a wide variety of malignant tumors. It results in chemotherapeutic resistance by depriving oxygen essential for the cytotoxic activities of these agents in tumor cells. In addition, hypoxia may reduce chemotherapeutic sensitivity through one or more indirect mechanisms including proteomic and genomic changes, which in turn results in increased invasiveness and metastatic potential, loss of apoptosis, and disordered angiogenesis, thereby increasing the incidence of chemotherapeutic resistance (Harrison and Blackwell, 2004).

Previously, it was found that hypoxic tumor cells in resting state were comparatively more resistant to chemotherapy in some cases (Harrison and Blackwell, 2004). And, oncogene was markedly up-regulated (Bando et al., 2003), while tumor suppressor gene was significantly down-regulated in a hypoxic condition (Lee et al., 2009).

Hypoxia-inducible factor 1 (HIF-1), a transcription factor in mammal, was first identified by Wang and his colleagues in hypoxia-induced cells in 1993 (Wang and Semenza, 1993). A series of studies have demonstrated that vascular growth factor (VEGF) (Yang et al., 2006), glucose transporter 1 (GLUT1) (Hayashi et al., 2004) genes were significantly increased along with HIF-1 in malignant tumors, which suggested that HIF-1 markedly enhanced the expression of oncogene in an anoxic environment. Further study confirmed that a powerful promoter of hypoxia-responsive element (HIF-1/HRE) was affected in the hypoxic condition (Dachs et al., 1997). Subsequently, it also showed that the HIF-1/HRE significantly promoted the expression of target gene HIF-
Ming-Dong Hu et al
Asian Pacific Journal of Cancer Prevention, Vol 13, 2012

1, leaving no obvious effect on the expressions of other oncogenes in the hypoxic environment (Post and Van Meir, 2001).

Jun activation domain-binding protein 1 (JAB1), a coactivator of activator protein 1 (AP-1), interacts with c-Jun and JunD, and selectively potentiates transactivation only by c-Jun, which promoted cell proliferation (Claret et al., 1996). JAB1 is a full-time specific suppressor for E2F1-induced tumor cells apoptosis (Hallstrom and Nevins, 2006). JAB1 and E2F1 co-expression synergistically induced cell apoptosis. In contrast, JAB1 could not synergize with E2F1 to promote cell cycle entry. Meanwhile, E2F1-induced apoptosis and induction of p53 accumulation could not be found in JAB1-depleted cells (Hallstrom and Nevins, 2006).

In this study, we amplified full-length human JAB1 fragment and then subcloned it into pUC57 containing 6×-HIF/HRE sequence to construct eukaryotic expression plasmid pUC57-HRE-JAB1. Subsequently, it was introduced into A549 cells. Following, the mRNA and protein level of JAB1 was investigated by qRT-PCR and western blot, respectively. And, the cell cycle and apoptosis of A549 cells were also assayed in the presence or absence of C-DDP. In view of this, we tried to illuminate the role of JAB1 in the chemotherapeutic resistance of lung cancer cells in an anoxic environment.

Materials and Methods

Materials

Fetal bovine serum (FBS), trypsin/EDTA, Geneticin (G418), T4 DNA ligase, SuperScript II reverse transcriptase, LipofectamineTM 2000, and TRizol reagent, were purchased from Invitrogen (Carlsbad, CA, USA). Matrigel was provided by BD Transduction Laboratories (CA, USA). C-DDP was a product of F. H. Faulding & Co. Ltd. (Adelaide, Australia).

Cell culture. A549 cells (human lung cancer cell line) were obtained from Shanghai Institutes of Biological Sciences (Shanghai, China) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics (100U/ml penicillin and 100 μg/ml streptomycin) at 37 °C in 5% CO₂.

Hypoxic culture (Maher et al., 2007). A549 cells were exposed to an hypoxic environment (0.3% O₂) in a hypoxia glove box (Coylab, Grass Lake, USA) for 24 h. Then the cells were transfected with pUC57-HRE and pUC57-HRE-JAB1. Meanwhile, 2 μg/ml C-DDP was added respectively. In addition, if medium was replaced after the hypoxic exposure, the replaced medium was equilibrated in an anoxic environment for 24 h before use.

Plasmid construction

Human JAB1 cDNA (NM. 006837) was amplified by RT-PCR with the oligonucleotides 5'-ATGGCCGGGCTCCGGGAGCGG-3' (forward primer) and 5'-TTAAAGAGATGTTAATTTGAT-3' (reverse primer) using mRNA isolated from A549 cells as template. The fragment was cloned into eukaryotic expressive vector pUC57 with a 6x-HIF/HRE sequence, and the resulting plasmid was named as pUC57-HRE-JAB1. The orientation and the sequence of the insert was verified by restriction digestion and sequencing.

Transfection of A549

A549 were grown to 70% to 80% confluence in 6-well plates. Cells were transfected with either pUC57-HRE (as negative control) or eukaryotic expressive plasmid pUC57-HRE-JAB1 using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Briefly, cells were incubated for 10 h in the medium containing plasmid, then, the transfection solution was removed by pipetting, and cells were allowed to recover for 48 h in growth medium. Cells were transferred into growth media containing 400 μg/ml G418 (Roche, USA) and cultured for 14 days to select positive cells. The cells used for the following experiments were named as A549/pUC57-HRE-JAB1 and control cells as A549/pUC57-HRE.

Quantitative real-time RT-PCR (qRT-PCR)

Total RNA was extracted from cells with TRizol reagent and the first-strand cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen). The expression of mRNA for human JAB1 was examined by qRT-PCR using SYBR green-based assays. The primer used for JAB1 is: forward: 5'- GCTCGGCGTGGCGACGGCTTA-3'; reverse: 5'- GTGCCCAATGTTGAGGAGC-3'. As an internal control, β-actin was analyzed in parallel by using the following primers: forward: 5'- GCCGAGGAGAACAAGGG-3'; reverse: 5' - TGG CTG TGC GCAGGT-3'. As an internal control, β-actin was analyzed in parallel by using the following primers: forward: 5' - GTG GCG CGC CCCAGGCACCA-3'; reverse: 5'- CTTCCCTAATGTCAAGCAGATCC-3'.

Western blot analysis

A549 cells were washed twice with phosphatebuffered saline (PBS) prior to lysis in pre-cooled RIPAlysatise (Pierce, USA) containing protease inhibitor cocktail. Protein concentrations were determined by Bradford protein assay (Bio-Rad, USA). The whole cell lysates (50μg) were separated with 12% SDS-PAGE and transferred to PVDF membrane. Then, the membranes were blocked 4 h with 5% milk in TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.5% Tween 20). The membrane was then incubated with mouse anti- human JAB1, mouse anti- human Caspase-3 monoclonal antibody, mouse anti- human cleaved Caspase-3 (BD Biosciences, USA) (1: 500), or mouse anti- human β-actin antibodies at 4 °C overnight, and HRP-conjugated goat anti- mouse IgG for an additional 1h at room temperature. After washing three times in TBST, enhanced chemiluminescence reagents (ECL) were used for the final detection.

MTT assay

A549/pUC57-HRE-JAB1, A549/pUC57-HRE and A549 cells were treated with C-DDP for 48 h. After 20 μl MTT (5 mg/ml) (Sigma, USA) was added to each well, cells were cultured in an anoxic environment (0.3% O₂) in a hypoxia glove box at 37 °C for 24 h. Then, the plates were centrifuged and the supernatant was discarded, and 150 μl of DMSO was added. When the formazan crystals
were dissolved, the optical density (OD) at 492 nm was measured using a microplate reader.

**Cell cycle and apoptosis analysis**

Cell cycle and apoptosis of the A549 cells after treatment were determined by FACS. Briefly, A549, A549/pUC57-HRE, A549/pUC57-HRE-JAB1 cells were subcultured in three plates respectively and cultured for 48 h, then washed with PBS and fixed in 70% ethanol and stained with PI solution (50 μg/ml propidium iodide, 1 mg/ml RNase). Cell cycle was determined by a flow cytometry (FACScan, Becton Dickinson, USA). To quantify apoptosis percentage, cells were stained with Annexin-V and PI using a Vybrant Apoptosis Assay Kit (Invitrogen, USA) according to the manufacturer’s instructions.

**Statistical analysis**

All data were expressed as mean ± standard deviation (SD). Comparisons between two groups were made with unpaired Student’s t-test. Non-parametric comparisons between three or more groups were made with ANOVA followed by Kruskal–Wallis post hoc analysis. P < 0.05 was considered statistically significant.

**Results**

**JAB1 mRNA and protein level up-regulation after pUC57-HRE-JAB1 transfection into A549 cells in hypoxia**

To investigate whether pUC57-HRE-JAB1 introduction into A549 cells would up-regulate JAB1 mRNA and protein level under hypoxia condition, A549 cells were transfected with the expression plasmid pUC57-HRE-JAB1. The levels of JAB1 mRNA and protein in transfected A549 cells were then analyzed by real-time PCR and western blot. Contrast to the group that transfected with the empty vector, pUC57-HRE, the levels of JAB1 mRNA and protein expression were increased in the group that transfected with the expression plasmid of JAB1 (Figure 1, 2). These results demonstrated that pUC57-HRE-JAB1 introduction could significantly promote JAB1 expression in a hypoxia environment.

**Upregulation of JAB1 inhibited cell proliferation**

After the transfection of pUC57-HRE-JAB1, the cell number began to increase at the second day. However, the cell was significantly less than that in A549 and A549/pUC57-HRE at the corresponding time point (Figure 3), suggesting pUC57-HRE-JAB1 efficiently inhibited the proliferation of A549 cells.

**Effect of pUC57-HRE-JAB1 on cell cycle and apoptosis of A549 cells**

The FACScan result showed that the cell number was significantly increased in G0/G1 and decreased in G2/M phase after the transfection of pUC57-HRE-JAB1. Further, PI in the A549/pUC57-HRE-JAB1 was significantly decreased compared with that in the A549 and A549/pUC57-HRE (P<0.05), suggesting the pUC57-HRE-JAB1 introduction arrested the cell cycle mainly in G0/G1 phase (Figure 4, Table 1).

In the presence of C-DDP, the cells were significantly increased in G0/G1 and decreased in G2/M. The cells were further increased in G0/G1 and decreased G2/M after treatment of pUC57-HRE-JAB1 introduction in combination with C-DDP. The PI in A549 cells was also significantly down-regulated after the treatment of pcDNA-HRE-JAB1 introduction in combination with C-DDP (Figure 4, Table 1).

**Figure 1. Effect of pUC57-HRE-JAB1 Introduction on mRNA Level of JAB1 in A549 Cells.**

The expression of JAB1 protein after pUC57-HRE-JAB1 introduction significantly higher than that in the control. However, the simple pUC57-HRE introduction could not up-regulate the expression of JAB1 protein. *P<0.01 versus A549; †P<0.01 versus A549/pUC57-HRE

**Figure 2. Effect of pUC57-HRE-JAB1 Introduction on Protein Expression of JAB1.**

The expression of JAB1 protein after pUC57-HRE-JAB1 introduction significantly higher than that in the control. However, the simple pUC57-HRE introduction could not up-regulate the expression of JAB1 protein. *P<0.01 versus A549; †P<0.01 versus A549/pUC57-HRE

**Figure 3. pUC57-HRE-JAB1 Introduction Suppressed the Cell Proliferation.**

Cells were digested by 0.1% trypsin, washed twice with PBS and stained with trypan blue. Finally, the live cells were counted. From the second day after the transfection, the cell number after pUC57-HRE-JAB1 introduction was significantly less than that in the A549 and A549/pUC57-HRE. *P<0.01 versus A549; †P<0.01 versus A549/pUC57-HRE
Table 1. Effect of pUC57-HRE-JAB1 Introduction on Cell Cycle Distribution of A549 Cells

| Treatment                        | G0/G1 (%) | S (%)     | G2/M (%) | PI (%)  |
|---------------------------------|-----------|-----------|----------|---------|
| A549                            | 50.6 ± 3.8| 40.8 ± 2.5| 8.6 ± 1.5| 49.1 ± 5.2|
| A549/pUC57-HRE                  | 50.3 ± 2.7| 39.7 ± 1.8| 10.0 ± 1.4| 49.2 ± 3.8|
| A549/ pUC57-HRE -JAB1           | 59.9 ± 4.5*| 35.3 ± 2.4| 4.8 ± 1.0*| 38.3 ± 3.6*|
| A549/ pUC57-HRE +C-DDP          | 61.3 ± 5.5*| 36.4 ± 3.9| 2.3 ± 0.5*| 38.1 ± 4.3*|
| A549/ pUC57-HRE -JAB1+C-DDP     | 61.1 ± 5.4*| 36.2 ± 3.4| 2.7 ± 0.6*| 37.6 ± 5.1*|
| A549/ pUC57-HRE -JAB1+C-DDP     | 72.6 ± 6.2** † ‡ | 27.3 ± 2.5* † | 1.1 ± 0.2** † ‡ | 27.6 ± 2.3** † ‡ |

*P<0.05, ** P<0.01 versus A549; †P<0.05 versus A549/pcDNA-HRE-JAB1; ‡P<0.05 versus A549+C-DDP; PI= (S+G2M)/(G0/G1+S+G2M)

Discussion

An imbalance between oxygen supply and consumption
Recently, JAB1 has been confirmed to be one specific apoptotic gene for tumor cells. And, it does work via regulating elongation factor E2F1 directly. E2F family genes are terminal factors in the “p16-CDK4/6-cyclin D-Rb-E2F” cell cycle control pathway, and E2F1 is also a p14ARF upstream regulator, which can enhance the ability of p53 to promote apoptosis by promoting the expression of p14ARF.

In 1996, Claret et al. screened out JAB1 from a human lymphocyte cDNA library using a yeast two-hybrid system (Claret et al., 1996). Then a subunit of COP9 signalosome (CSN) was found to be an autophagy of JAB1 in Arabidopsis thaliana (Tomoda et al., 2002). JAB1 could specifically interact with p27kip1 and enable p27kip1 to shuttle and move to the cytoplasm, thereby reducing intracellular p27kip1 content via accelerating its degeneration (Kouvaraki et al., 2003; Shintani et al., 2003). Studies have furthermore shown that JAB1 was expressed in many tumors such as pancreatic cancer (Kouvaraki et al., 2006), lung cancer (Osoegawa et al., 2006), lymphoma (Wang et al., 2007), and etc. It has been reported that p27kip1 level was significantly reduced after the introduction of Jab1 gene into breast cancer cells (Kouvaraki et al., 2003). Further, the reduced expression of p27kip1 was closely related to the proliferation activity and invasiveness of laryngeal squamous cell carcinoma (LSCC) (Tamura et al., 2001). And, the proliferation was associated with the development and prognosis of the tumor. In fact, the role of JAB1 in apoptosis is disputable. Liu et al. found that co-expression of JAB1 and Bcl-Gonad short form (BclGs) synergistically induces apoptosis of HeLa cells (Liu et al., 2008). JAB1 could compete with Bcl-XL/Bcl-2 to bind to BclGs, thereby promoting the cells apoptosis. Reversely, RNAi-mediated knock-down of JAB1 gene markedly reduced the proapoptotic activity of BclGs.

In the present study we also found that the overexpression of JAB1 in A549 cells significantly increased the cells apoptosis in the absence or presence of C-DDP, suggesting the apoptotic promotion role of JAB1. And, the cell apoptosis was arrested at G1/S phase, which was consistent to the study of Tomoda et al. in some degree (Tomoda et al., 2004). They found that Jab1-/- embryonic cells lacking other CSN components expressed comparatively higher levels of p53, p27, and cyclin E, thereby resulting in impaired proliferation and accelerated apoptosis. However, the amount of Jab1-containing small subcomplex in Jab1-/- mouse embryonic fibroblast cells was decreased, they proliferated poorly, and the cell cycle was delayed in the progression from G1 to S phase compared with the wild-type cells. All the findings suggested that Jab1 might control cell cycle progression and cell survival via regulating multiple cell cycle signaling pathways (Tomoda et al., 2004).

In summary, as a specificity factor for E2F1-induced apoptosis, JAB1 overexpression enhances chemotherapeutic sensitivity of lung cancer cell line A549 in an anoxic environment, which might be associated with the increased cell apoptosis. Importantly, it might have the potential to improve the efficacy of chemotherapy in the treatment of lung cancer in the clinic.
Acknowledgements

This study was supported by a grant of Natural Science Foundation of China (No. 30801366).

References

Bando H, Toi M, Kitada K, Koike M (2003). Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. *Biomed Pharmacother*, 57, 333-40.

Cheah PL, Looi LM, Teoh KH, Mun KS, Nazarina AR (2012). p16INK4a is a useful marker of human papillomavirus integration allowing risk stratification for cervical malignancies. *Asian Pac J Cancer Prev*, 13, 469-72.

Claret FX, Hibi M, Dhut S, Toda T, Karin M (1996). A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. *Nature*, 383, 453-7.

Dachs GU, Patterson AV, Firth JD, et al (1997). Targeting gene expression to hypoxic tumor cells. *Nat Med.*, 3, 515-20.

Harrison L, Blackwell K (2004). Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? *OncoLogic*, 5, 31-40.

Hayashi M, Sakata M, Takeda T, et al (2004). Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells. *J Endocrinol.*, 183, 145-54.

Kouvaraki MA, Korapati AL, Rassidakis GZ, et al (2006). Potential role of Jun activation domain-binding protein 1 as a negative regulator of P27kip1 in pancreatic adenocarcinoma. *Cancer Res.*, 66, 8581-9.

Kouvaraki MA, Rassidakis GZ, Tian L, et al (2003). Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27kip1. *Cancer Res.*, 63, 2977-81.

Lara PC, Lloret M, Clavo B, et al (2009). Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. *Radiat Oncol.*, 4, 29.

Lee SH, Kim J, Kim WH, Lee YM (2009). Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. *Oncogene*, 28, 184-94.

Liang HY, Wang GP, Gu LJ, et al (2012). HIF-1α siRNA and cisplatin in combination suppress tumor growth in a nude mouse model of esophageal squamous cell carcinoma. *Asian Pac J Cancer Prev*, 13, 469-72.

Liu X, Pan Z, Zhang L, et al (2008). JAB1 accelerates mitochondrial apoptosis by interaction with proapoptotic BclGs. *Cell Signal.*, 20, 230-40.

Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*, 25, 402-8.

Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ (2007). Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. *Mot Cancer Ther*, 6, 732-41.

Osoegawa A, Yoshino I, Kometani T, et al (2006). Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. *Cancer*, 107, 154-61.

Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. *Oncogene*, 23, 2934-49.

Post DE, Van Meir EG (2001). Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. *Gene Ther*, 8, 1801-7.

Ruan H, Su H, Hu L, et al (2001). A hypoxia-regulated adenovirus vector for cancer-specific gene therapy. *Neoplasia*, 3, 255-63.

Semenza GL (1999). Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol*, 15, 511-78.

Semenza GL (2000). HIF-1: mediator of physiological and pathophysiologic responses to hypoxia. *J Appl Physiol*, 88, 1474-80.

Semenza GL, Jiang BH, Leung SW, et al (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. *J Biol Chem*, 271, 32529-37.

Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H (2003). Skp2 and Jab1 expression are associated with inverse expression of p27kip1 and poor prognosis in oral squamous cell carcinomas. *Oncology*, 65, 355-62.

Tamura N, Dong Y, Sui L, et al (2001). Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas. *J Laryngol Otol*, 115, 400-6.

Toh CK (2009). The changing epidemiology of lung cancer. *Methods Mol Biol*, 472, 397-411.

Tomoda K, Kubota Y, Arata Y, et al (2002). The cytoplasmic shuttling and subsequent degradation of p27kip1 mediated by JAB1/CSN5 and the COP9 signalosome complex. *Biol Chem*, 277, 2302-10.

Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato JY (2004). Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. *J Biol Chem*, 279, 43013-8.

Wang GL, Semenza GL (1993). General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci U S A*, 90, 4304-8.

Wang YC, Fei M, Cheng C, et al (2007). Jun Activation Domain-Binding Protein 1 negatively regulate p27 (kip1) in Non-Hodgkin’s Lymphomas. *Cancer Biol Ther*, 7, 460-7.

Xie QC, Hu YD, Wang LL, et al (2005). The co-transfection of p16 (INK4a) and p14 (ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity. *Colloids Surf B Biointerfaces*, 46, 188-96.

Yang QC, Zeng BF, Shi ZM, et al (2006). Inhibition of hypoxia-inducible factor-1 confers resistance to cisplatin in combination suppresstumor growth in a nude mouse model of esophageal squamous cancer cell line Eca109. *Asian Pac J Cancer Prev*, 6, 271.

Yasuda H (2008). Solid tumor physiology and hypoxia-induced pathophysiological responses to hypoxia. *Annu Rev Physiol*, 70, 15-37.